Figure 1.
2D gel electrophoresis separation of urinary and recombinant hCG products (6,500 IU loaded).
(A) u-hCG manufacturer A. (B) u-hCG Manufacturer B. (C) r-hCG Manufacturer D. (D) Zoom views on the regions of gels (A) and (B) with spots containing PrP peptides encircled.
Table 1.
Non-gonadotropin protein profile identified in u-hCG products.
Figure 2.
Human prion protein (PrP) sequence (mature form in bold).
*Tryptic peptides identified in human chorionic gonadotropin (hCG) preparations (PrP 121-136, PrP 137-148, PrP 157-164, PrP 209-220, and PrP 221-228) are underlined.
Figure 3.
2D gel electrophoresis separation of urinary hMG and recombinant hFSH/hLH products.
(A) hMG Manufacturer A (600 IU loaded). (B) hMG Manufacturer C (1,125 IU loaded). (C) r-hFSH/r-hLH Manufacturer D (1,125 IU loaded).
Figure 4.
2D gel electrophoresis separation of highly purified urinary hMG and recombinant hFSH/hLH products (1,125 IU loaded).
(A) hMG-HP Manufacturer A-Product 1. (B) hMG-HP Manufacturer A-Product 2. (C) r-hFSH/r-hLH Manufacturer D.
Table 2.
Non-gonadotropin protein profile identified in hMG-HP products.
Table 3.
Results of prion protein peptides analysis in gonadotropin preparations by LC-SRM.
Table 4.
Characteristics of commercial products analyzed.
Table 5.
Optimized transitions for prion protein native peptides and isotope labeled standard peptides.